HAVN — HAVN Life Sciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro CapValue Trap
- CA$0.59m
- CA$0.60m
- CA$0.28m
Annual income statement for HAVN Life Sciences, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0.276 |
| Cost of Revenue | |||
| Gross Profit | — | — | 0.09 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 0.041 | 30.4 | 22.7 |
| Operating Profit | -0.041 | -30.4 | -22.4 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -0.041 | -30.4 | -22.4 |
| Net Income After Taxes | -0.041 | -30.4 | -22.4 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.041 | -30.4 | -22.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.041 | -30.4 | -22.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.018 | -15.5 | -2.31 |
| Dividends per Share |